Bullish & Foolish
Full OGEN fundamentals All 466 on the Survival Watch

OGENORAGENICS, INC.

Is Oragenics struggling financially?

Yes, by its own account. Oragenics told the SEC on 20 May 2026, in Form DEF 14A, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

7/100

Critical

Sector
Biotech/Pharma
Market cap
$2.4M
Source filing
DEF 14A 20 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 2months

    If the burn speeds up

    Empty by Aug 2026

  • 4months

    If it eases off

    Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$3.9M

÷

Cash burned over the last 12 months

$15.8M

What Oragenics told the SEC

…or modified as to uncertainty, audit scope, or accounting principles, except for the following: The report included an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern as a result of its recurring o perating losses, negative operating cash flows and accumulated deficit. The Board has directed that the Company submit the selection of Cherry Bekaert as…

ORAGENICS, INC., Form DEF 14A, filed 20 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 547.9% share-count increase The company issued stock. Each share now owns 84.6% less of the business than a year ago, before any change in the price.
  • Cash burn is increasing It is spending 12% more cash per year than it was, so the runway above shortens even if nothing else changes.

Other Biotech/Pharma companies that filed the doubt